Document Detail


Telmisartan lowers home blood pressure and improves insulin resistance without correlation between their changes.
MedLine Citation:
PMID:  21269058     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Telmisartan is an angiotensin type 1 receptor blocker (ARB), which also partially activates liganding peroxisome proliferator-activated receptor gamma. However, the relationship between the effects of telmisartan on hemodynamics and metabolism has not sufficiently been elucidated in clinical settings. We examined the long-term effects of telmisartan on hemodynamics including home blood pressure (BP) and on insulin resistance representing as homeostasis model assessment (HOMA-R). Twenty-seven hypertensive patients were consecutively enrolled at our outpatient department. At entry, all of the participants were previously prescribed another ARB for more than 3 months and then the former ARB were replaced by telmisartan. Hemodynamic and metabolic parameters were measured before treatment and at points 1 and 3 months after treatment with telmisartan. Telmisartan significantly lowered home systolic blood pressure (SBP) and diastolic blood pressure (DBP) (DBP) and improved HOMA-R during the treatment period. However, the changes in home SBP and DBP were not correlated with that of HOMA-R. In conclusion, telmisartan lowers home BP and improves insulin resistance without correlation between their changes.
Authors:
Kazuhiro Kobayashi; Yoichi Ohno; Tsuneo Takenaka; Naofumi Ikeda; Hirokazu Okada; Yoshihiko Kanno; Hiromichi Suzuki
Related Documents :
2277408 - Histological and histometrical study of myocardial fibrosis in spontaneously hypertensi...
2676248 - Effect of metoprolol on serial measurements of exchangeable sodium, blood pressure, ren...
10545438 - Chromosomal mapping of quantitative trait loci that influence renal hemodynamic functions.
20865358 - Perinatal l-arginine and antioxidant supplements reduce adult blood pressure but not am...
23102118 - Cardiovascular risk factors, cortisol, and amyloid-β deposition in alzheimer's disease...
15204388 - Biomechanical properties of the anterior urethra of the male rabbit--a study using impe...
Publication Detail:
Type:  Journal Article     Date:  2011-01-26
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  33     ISSN:  1525-6006     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  2011  
Date Detail:
Created Date:  2011-03-22     Completed Date:  2011-07-15     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  100-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Benzimidazoles / therapeutic use*
Benzoates / therapeutic use*
Blood Glucose / metabolism
Blood Pressure / drug effects*
Blood Pressure Monitoring, Ambulatory
Humans
Hypertension / blood,  drug therapy*,  physiopathology*
Insulin / blood
Insulin Resistance*
Lipids / blood
Middle Aged
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Blood Glucose; 0/Insulin; 0/Lipids; U5SYW473RQ/telmisartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of the Hypotensive and Bradycardic Activity of Ginkgo, Garlic, and Onion Extracts.
Next Document:  Association of the Human CYP11B2 Gene and Essential Hypertension in Southwest Han Chinese Population...